Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC

Inclusion Criteria: * Age ≥ 18 years * Hepatocellular carcinoma confirmed with pathology or identified with radiological images with typical features * patient with unresectable primary hepatocellular carcinoma * Child-Pugh Class A or B, score ≤ 7 * ECOG score 0-2 * Expected survival time not less than 12 weeks * At least one tumor nodule with one uni-dimension of ≥ 1 cm * Peripheral platelet of or more than 50×10(9)/L * Peripheral hemoglobin of or more than 85g/L * Peripheral albumen of or more than 28g/L * Total bilirubin ≤3.0mg/dl * ALT and AST ≤ 5.0 x the upper limit of normal * Serum amylase ≤ 1.5x the upper limit of normal * Serum creatinine ≤ 1.5x upper limit of normal * PT-INR\<2.3 or PT prolong no more than 4s of normal Exclusion Criteria: * Congestive heart failure \> NYHA class 2 * History of active coronary disease( except myocardial infarction more than 6 months ago) * Receive anti-arrhythmia treatment(except β-receptor blocker,calcium channel blocker and digoxin) * uncontrollable hypertension * Active clinically serious infections (\> 2 NCI-CTC Version 3.0) * History of HIV infection * Inclined to hemorrhage or active hemorrhage with 1 month * Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in this study * Pregnant or breast-feeding.Women of childbearing potential must have a negative pregnancy test performed within 7 days prior to enrolling in this portion of the study * Known or suspected allergy to any agent given in association with this trial * Concomitant anti-cancer therapy (except immunotherapy and Chinese traditional treatment) * Surgical operation within 4 weeks prior to enrolling in this portion of the study